Last reviewed · How we verify
Sitafloxacin (S)
Sitafloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV.
Sitafloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV. Used for Community-acquired pneumonia, Nosocomial pneumonia, Skin and soft tissue infections.
At a glance
| Generic name | Sitafloxacin (S) |
|---|---|
| Sponsor | Shenzhen Third People's Hospital |
| Drug class | fluoroquinolone antibiotic |
| Target | DNA gyrase and topoisomerase IV |
| Modality | Small molecule |
| Therapeutic area | Infectious diseases |
| Phase | Phase 3 |
Mechanism of action
This inhibition prevents bacterial DNA replication and transcription, ultimately leading to bacterial cell death. Sitafloxacin's mechanism of action is similar to other fluoroquinolones, but with a broader spectrum of activity against Gram-positive and Gram-negative bacteria.
Approved indications
- Community-acquired pneumonia
- Nosocomial pneumonia
- Skin and soft tissue infections
Common side effects
- Nausea
- Diarrhea
- Vomiting
Key clinical trials
- A PAN-USR TB Multi-Center Trial (PHASE3)
- Ultra-Short Regimen for Elderly DS-TB (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sitafloxacin (S) CI brief — competitive landscape report
- Sitafloxacin (S) updates RSS · CI watch RSS
- Shenzhen Third People's Hospital portfolio CI